Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL

Martin Neumann, MD, Sandra Heesch, PhD, Cornelia Schlee, MS, Stefan Schwartz, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Thorsten Raff, MD, Monika Brueggemann, Wolf-Karsten Hofmann, Stefan K Bohlander, MD, Philipp A Greif, MD, Claudia D Baldus

Blood (2012) 120 (21): 1377.

https://doi.org/10.1182/blood.V120.21.1377.1377

Published: 2012

Journal Articles

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Nicola Goekbuget, MD, Daniel Stanze, MD, Renate Arnold, Monika Brueggemann, MD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Wolf-Dieter Ludwig, Georg Maschmeyer, MD, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Hubert Serve, MD, Michael Kneba, MD, Dieter Hoelzer, MD

Blood (2011) 118 (21): 250.

https://doi.org/10.1182/blood.V118.21.250.250

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Nicola Goekbuget, MD, Monika Brueggemann, MD, Renate Arnold, MD, Claus-Rainer Bartram, PhD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, Georg Maschmeyer, MD, Dorle Messerer, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 90.

https://doi.org/10.1182/blood.V114.22.90.90

Published: 2009

Journal Articles

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Sebastian Boettcher, MD, Stephan Stilgenbauer, MD, PhD, Raymonde Busch, Monika Brüggemann, MD, PhD, Thorsten Raff, MD, Kirsten Fischer, MD, Günter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Christiane Pott, MD, Hartmut Döhner, MD, PhD, Michael Hallek, MD, PhD, Michael Kneba, MD, PhD, Matthias Ritgen, MD, on Behalf Of GCLLSG

Blood (2008) 112 (11): 3139.

https://doi.org/10.1182/blood.V112.11.3139.3139

Published: 2008

Journal Articles

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

Matthias Ritgen, MD, Monika Brueggemann, MD, PhD, Sebastian Boettcher, MD, Thorsten Raff, MD, Christiane Pott, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Peter Dreger, MD

Blood (2008) 112 (11): 3503.

https://doi.org/10.1182/blood.V112.11.3503.3503

Published: 2008

Journal Articles

MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.

Monika Brüggemann, MD, Thorsten Raff, MD, Christiane Pott, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Renate Arnold, MD, Dieter Hoelzer, MD, Nicola Goekbuget, MD, Michael Kneba, MD

Blood (2007) 110 (11): 2799.

https://doi.org/10.1182/blood.V110.11.2799.2799

Published: 2007

Journal Articles

Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

Christiane Pott, MD, Sebastian Boettcher, MD, Monika Brueggemann, MD, Thorsten Raff, MD, Matthias Ritgen, MD, Michael Unterhalt, MD, Martin Dreyling, MD, Wolfgang Hiddemann, MD, Eva Hoster, MS, Michael Kneba, MD

Blood (2006) 108 (11): 2414.

https://doi.org/10.1182/blood.V108.11.2414.2414

Published: 2006

Journal Articles

Sensitivity and Applicability of Six-Color Flow Cytometry Is Comparable to ASO-Primer-Real-Time PCR (RQ-PCR) for Minimal Residual Disease (MRD) Monitoring in Adult Acute Lymphoblastic Leukemia (ALL) - A Comparative Analysis in 70 Patients from the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL).

Sebastian Boettcher, MD, Sebastian Irmer, MD, Silke Lueschen, PhD, Matthias Ritgen, MD, Thorsten Raff, MD, Nicola Goekbuget, MD, Dieter Hoelzer, MD, Heinz-August Horst, MD, Michael Kneba, MD, PhD, Monika Brueggemann, MD

Blood (2006) 108 (11): 2287.

https://doi.org/10.1182/blood.V108.11.2287.2287

Published: 2006

Journal Articles

Measurement of Minimal Residual Disease (MRD) after Consolidation Therapy as a Means of Early Detection of Relapse in Adult Acute Lymphoblastic Leukemia (ALL).

Michael Kneba, MD, PhD, Monika Brüggemann, MD, Nicola Gökbuget, MD, Regina Reutzel, Dieter Hoelzer, MD, PhD, Thorsten Raff, MD

Blood (2005) 106 (11): 538.

https://doi.org/10.1182/blood.V106.11.538.538

Published: 2005

Journal Articles

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

Nicola Goekbuget, MD, Renate Arnold, MD, Johannes Atta, MD, Patrick Brück, MD, Stella Hermann, MD, Heinz Horst, MD, Mustafa Kondakci, MD, Roswitha Kotthoff, Oliver Ottmann, MD, Thorsten Raff, MD, Richard Ratei, MD, Mathias Schmid, MD, Michael Stadler, MD, Dieter Hoelzer, MD, PhD

Blood (2005) 106 (11): 150.

https://doi.org/10.1182/blood.V106.11.150.150

Published: 2005

Journal Articles

MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL).

Matthias Ritgen, MD, Sebastian Boettcher, MD, Stephan Stilgenbauer, MD, Hartmut Dohner, MD, Monika Brueggeman, MD, Christine Pott, MD, Thorsten Raff, MD, Norbert Schmitz, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Peter Dreger, MD

Blood (2005) 106 (11): 714.

https://doi.org/10.1182/blood.V106.11.714.714

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.

Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

Measurement of Minimal Residual Disease (MRD) after Consolidation Therapy as a Means of Early Detection of Relapse in Adult Acute Lymphoblastic Leukemia (ALL).

Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT).

MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only